Cargando…

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination

BACKGROUND: Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent activation of effector cells, including natural k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagstaffe, Helen R, Clutterbuck, Elizabeth A, Bockstal, Viki, Stoop, Jeroen N, Luhn, Kerstin, Douoguih, Macaya, Shukarev, Georgi, Snape, Matthew D, Pollard, Andrew J, Riley, Eleanor M, Goodier, Martin R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030727/ https://www.ncbi.nlm.nih.gov/pubmed/31821493 http://dx.doi.org/10.1093/infdis/jiz657

Ejemplares similares

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
por: Wagstaffe, Helen R., et al.
Publicado: (2020)

Durable natural killer cell responses after heterologous two-dose Ebola vaccination
por: Wagstaffe, Helen R., et al.
Publicado: (2021)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
por: Mutua, Gaudensia, et al.
Publicado: (2019)

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
por: Goldstein, Neil, et al.
Publicado: (2020)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
por: Anywaine, Zacchaeus, et al.
Publicado: (2019)

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
por: Wagstaffe, Helen R., et al.
Publicado: (2022)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Alexandre, Marie, et al.
Publicado: (2023)

Vaccinating for natural killer cell effector functions
por: Wagstaffe, Helen R, et al.
Publicado: (2018)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
por: Pasin, Chloé, et al.
Publicado: (2019)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
por: Bockstal, Viki, et al.
Publicado: (2022)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Barry, Houreratou, et al.
Publicado: (2021)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Roozendaal, Ramon, et al.
Publicado: (2020)

IL-15 Promotes Polyfunctional NK Cell Responses to Influenza by Boosting IL-12 Production
por: Wagstaffe, Helen R., et al.
Publicado: (2018)

Ebola or Not? Evaluating the Ill Traveler From Ebola-Affected Countries in West Africa
por: Fairley, Jessica K., et al.
Publicado: (2016)

EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country
por: Mooney, Thomas, et al.
Publicado: (2018)

High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection
por: Michelow, Ian C., et al.
Publicado: (2011)

Variability in Intrahousehold Transmission of Ebola Virus, and Estimation of the Household Secondary Attack Rate
por: Glynn, Judith R, et al.
Publicado: (2018)

Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses
por: Gunn, Bronwyn M, et al.
Publicado: (2020)

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
por: Afolabi, Muhammed O, et al.
Publicado: (2022)

Natural Killer Cells Dampen the Pathogenic Features of Recall Responses to Influenza Infection
por: Mooney, Jason P., et al.
Publicado: (2020)

Ebola, the killer virus
por: Ghazanfar, Haider, et al.
Publicado: (2015)

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
por: McLean, Chelsea, et al.
Publicado: (2023)

The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a Médecins Sans Frontières Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014
por: Fitzpatrick, Gabriel, et al.
Publicado: (2015)

Ebola Virus Disease and Pregnancy: A Retrospective Cohort Study of Patients Managed at 5 Ebola Treatment Units in West Africa
por: Henwood, Patricia C., et al.
Publicado: (2017)

First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease
por: Dörnemann, Jenny, et al.
Publicado: (2017)

Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells
por: Clutterbuck, Elizabeth A., et al.
Publicado: (2012)

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
por: Nyombayire, Julien, et al.
Publicado: (2022)

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo
por: Watson-Jones, Deborah, et al.
Publicado: (2022)

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
por: Ishola, David, et al.
Publicado: (2022)

Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia
por: Fausther-Bovendo, Hugues, et al.
Publicado: (2021)

Accessing Maternal Health Services in Eastern Burma
por: Douoguih, Macaya
Publicado: (2008)

Infectious Disease Physician Assessment of Hospital Preparedness for Ebola Virus Disease
por: Polgreen, Philip M., et al.
Publicado: (2015)

Role of Key Infectivity Parameters in the Transmission of Ebola Virus Makona in Macaques
por: de La Vega, Marc Antoine, et al.
Publicado: (2021)

Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection
por: Dowall, Stuart David, et al.
Publicado: (2016)

Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection
por: Rimoin, Anne W, et al.
Publicado: (2018)

The Impact of Different Types of Violence on Ebola Virus Transmission During the 2018–2020 Outbreak in the Democratic Republic of the Congo
por: Kelly, John Daniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qp7j0vd843u57k27idh7jor11v